GSK announced Wednesday that it will acquire an experimental treatment for non-alcoholic fatty liver disease, a liver disease, for up to $2bn.

The British pharmaceutical company said it had reached an agreement with US-based Boston Pharmaceuticals to acquire its lead drug candidate, efimosfermin, currently in phase III development.

Under the terms of the deal, GSK will pay Boston an initial $1.2bn, with up to $800m in milestone payments based on the product's progress.

Efimosfermin is currently undergoing clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), including cirrhosis, and alcohol-related liver disease (ALD), two forms of steatohepatitis (SLD).

Although SLD—characterized by the accumulation of fat in the liver—affects around 5% of the global population, few treatment options currently exist for patients.

GSK, which is looking to strengthen its portfolio of projects in immune and inflammatory diseases, explains that the transaction will enable it to consolidate its franchise in hepatology, where it is already present in the treatment of chronic hepatitis B.

GSK are up 1% in London on Wednesday morning following this announcement.


Copyright (c) 2025 CercleFinance.com. All rights reserved.